Standout Papers

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer 2011 2026 2016 2021 1.7k
  1. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer (2011)
    José Baselga, Javier Cortés et al. New England Journal of Medicine
  2. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer (2015)
    Sandra M. Swain, José Baselga et al. New England Journal of Medicine
  3. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer (2017)
    Gϋnter von Minckwitz, Marion Procter et al. New England Journal of Medicine
  4. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study (2013)
    Sandra M. Swain, Sung‐Bae Kim et al. The Lancet Oncology

Immediate Impact

8 by Nobel laureates 20 from Science/Nature 80 standout
Sub-graph 1 of 21

Citing Papers

Mechanisms driving the immunoregulatory function of cancer cells
2023 Standout
In vivo hematopoietic stem cell modification by mRNA delivery
2023 StandoutScienceNobel
1 intermediate paper

Works of Mark Benyunes being referenced

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
2015 Standout
Cataracts after bone marrow transplantation: Long-term follow-up of adults treated with fractionated total body irradiation
1995

Author Peers

Author Last Decade Papers Cites
Mark Benyunes 4461 530 540 1960 1459 37 5.9k
Mark S. Berger 4535 1084 730 2021 1213 67 6.8k
Cristina Oliva 4700 175 575 1290 1995 66 6.1k
José Luiz Pedrini 4021 98 260 1512 1404 25 4.9k
Beth Overmoyer 4322 369 410 864 1250 142 6.0k
Svetislava J. Vukelja 4096 245 353 994 922 82 5.1k
Guenther G. Steger 4434 234 264 1044 1433 155 5.8k
John Gutheil 2262 170 396 1215 809 38 4.1k
Michaela Lehle 4082 757 378 1163 3979 40 7.3k
David Miles 5878 105 535 2655 2119 92 8.2k
Manfred Welslau 3994 186 1134 1530 1413 78 5.2k

All Works

Loading papers...

Rankless by CCL
2026